Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naive patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial.

ABSTRACT:

Background

In patients with untreated CD20-positive diffuse large B-cell lymphoma (DLBCL), a phase 3 trial was carried out to evaluate the efficacy and safety of zuberitamab plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; Hi-CHOP) versus rituximab plus CHOP (R-CHOP) treatment regimens.

Methods

In a 2:1 ratio, eligible patients were assigned randomly to receive treatment of six cycles of either 375 mg/m² zuberitamab or rituximab together with conventional CHOP chemotherapy. The objective response rate (ORR) at C6D50 served as the primary endpoint, and a non-inferiority margin of 10% was established. The secondary endpoints included the complete response (CR) rate at C6D50, duration of response (DOR), progression-free survival (PFS) and event-

SUBMITTER: Li Z 

PROVIDER: S-EPMC11529747 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature